Allocation of Retained Earnings to Capital Investment and Research and Development
First written in FY2016. 12 of 23 entries say "Advanced", first in FY2018. Latest entry: FY2027-H1.
21 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「The investing activities resulted in funds used of ¥2,006 million, compared with funds provided of ¥471 million in the same period of the previous year. This was mainly due to cash outflows including ¥1,761 million for the acquisition of property, plant and equipment and ¥109 million for the acquisition of intangible assets.」
During the interim consolidated accounting period, the company acquired ¥1,761 million of property, plant and equipment and ¥109 million of intangible assets, continuing to allocate funds to equipment and its business infrastructure. - 2026-09-01AdvancedGovernance
「▼ Research and development and technological innovation」
The company positioned R&D and technological innovation as key drivers of value expansion and cited proprietary product development and new handling technologies. - FY2026AdvancedAnnual report
「Capital investment during the consolidated fiscal year totaled ¥4,533 million, mainly for construction of a multistory parking facility at the company's head office, land acquisition by a subsidiary and office expansion work.」
The company made ¥4,533 million in capital investments. Research and development expenses also totaled ¥1,927 million, and it continued allocating funds to facilities and research and development. - 2026-04-30AdvancedOther Disclosures
「Investment: approximately ¥20.5 billion」
The company specified an investment of approximately ¥20.5 billion for major facilities supporting R&D and headquarters functions, including planned construction starts and completion dates for a multistory parking structure and a new headquarters building. - FY2026-H1RestatedAnnual report
「Total research and development expenses for the current interim consolidated accounting period amounted to ¥737 million. There were no material changes in the status of the Group's research and development activities during the current interim consolidated accounting period.」
The company recorded ¥737 million in research and development expenses and continued allocating funds to research and development. - FY2025-Q1RestatedAnnual report
「Total research and development expenses for the first quarter of the current consolidated cumulative period amounted to ¥287 million. There were no material changes in the status of the Group's research and development activities during the first quarter of the current consolidated cumulative period.」
The company recorded ¥287 million in research and development expenses and continued allocating funds to research and development. It stated that there were no significant changes in the status of its research and development activities. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥1,013 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company recorded ¥1,013 million in research and development expenses and continued allocating funds to research and development. It stated that there were no significant changes in the status of its research and development activities. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥616 million. There were no material changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company recorded ¥616 million in research and development expenses and continued allocating funds to research and development. It stated that there were no significant changes in the status of its research and development activities. - FY2023AdvancedAnnual report
「Capital investment during the consolidated fiscal year totaled ¥3,620 million in the Semiconductor and FPD-related Business and ¥1,032 million in the Life Science Business, for a total of ¥4,653 million. The main investments were completion of a new factory at the Vietnamese subsidiary and expansion of its production facilities.」
The company made ¥4,653 million in capital investments, including completion of the new Vietnamese factory and expansion of production facilities, allocating retained earnings and other funds to strengthen its facilities. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the third quarter of the current consolidated cumulative period amounted to ¥733 million. There were no material changes in the status of the Group's research and development activities during the third quarter of the current consolidated cumulative period.」
The company recorded ¥733 million in research and development expenses and continued allocating funds to research and development. It stated that there were no significant changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥438 million. There were no material changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company recorded ¥438 million in research and development expenses and continued its research and development activities. It stated that there were no significant changes in the status of those activities. - FY2023-Q1RestatedAnnual report
「Research and development expenses totaled ¥228 million for the first three months of the consolidated fiscal year. There were no significant changes in the status of the Group's research and development activities during the first three months of the consolidated fiscal year.」
The company recorded ¥228 million in research and development expenses and continued its research and development activities. It stated that there were no significant changes in the status of those activities. - FY2022-Q3RestatedAnnual report
「Research and development expenses totaled ¥565 million for the first nine months of the consolidated fiscal year. There were no significant changes in the status of the Group's research and development activities during the first nine months of the consolidated fiscal year.」
The company recorded ¥565 million in research and development expenses and continued its research and development activities. It stated that there were no significant changes in the status of those activities. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the second quarter of the current consolidated cumulative period amounted to ¥339 million. There were no material changes in the status of the Group's research and development activities during the second quarter of the current consolidated cumulative period.」
The company recorded ¥339 million in research and development expenses and continued directing retained earnings and other funds to research and development. It stated that there were no significant changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「Research and development expenses totaled ¥197 million for the first three months of the consolidated fiscal year. There were no significant changes in the status of the Group's research and development activities during the first three months of the consolidated fiscal year.」
The company recorded ¥197 million in research and development expenses in the first quarter and continued its research and development activities. It stated that there were no significant changes in the status of those activities. - FY2021AdvancedAnnual report
「Capital investment during the consolidated fiscal year totaled ¥1,980 million, primarily for expansion of a new factory at the Korean subsidiary.」
The company made ¥1,980 million in capital investments, mainly for expansion of the new factory at the Korean subsidiary, and continued to develop its facilities. - FY2021-Q3AdvancedAnnual report
「Research and development expenses totaled ¥306 million for the first nine months of the consolidated fiscal year. There were no significant changes in the status of the Group's research and development activities during the first nine months of the consolidated fiscal year.」
The company continued its research and development activities and reported total research and development expenses of ¥306 million for the first nine months. - FY2020AdvancedAnnual report
「Total capital investment during the consolidated fiscal year was ¥6,041 million, mainly for construction of a plant at the Vietnamese subsidiary and related investments in machinery and equipment.」
The company continued capital investment using retained earnings and other funds, investing ¥6,041 million during the fiscal year, mainly in construction of the Vietnamese factory and machinery and equipment. - FY2020-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥2,967 million, compared with ¥1,653 million used in the same period of the previous year. This was mainly due to ¥2,899 million in payments for the acquisition of property, plant and equipment.」
The company spent ¥2,899 million on the acquisition of property, plant and equipment during the first six months of the consolidated fiscal year, continuing its capital investment. - FY2019AdvancedAnnual report
「Capital investment during the consolidated fiscal year totaled ¥4,519 million, primarily for construction of a factory at the Vietnamese subsidiary and related investment in machinery and equipment.」
The company made ¥4,519 million in capital investments, mainly in construction of the Vietnamese factory and machinery and equipment. - FY2019-Q2AdvancedAnnual report
「Net cash used in investing activities was ¥1,653 million, compared with ¥528 million used in the same period of the previous year. This was mainly due to ¥1,604 million in payments for the acquisition of property, plant and equipment.」
The company spent ¥1,604 million on the acquisition of property, plant and equipment during the first six months of the consolidated fiscal year, continuing its capital investment. - FY2018AdvancedAnnual report
「Capital investment during the consolidated fiscal year totaled ¥1,701 million, primarily for construction of the fourth factory at the Vietnamese production subsidiary.」
The company directed retained earnings and other funds to production facilities, making ¥1,701 million in capital investments, including construction of the fourth factory at its Vietnamese production subsidiary. - FY2016First statedAnnual report
「We will allocate retained earnings to capital investment to strengthen our business base and to research and development investment in new technologies, thereby working to strengthen our management foundation over the long term.」
A capital allocation policy of directing retained earnings to production facilities and new technology development.